A panelist discusses how treating Demodex blepharitis led to successful reversal of contact lens intolerance in a young patient, highlighting the importance of addressing underlying ocular surface conditions.

The trial met its primary endpoint with statistical significance for the 150mg BID dose, with a proptosis responder rate of 52% (p=0.01).

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

RayTrace has been utilized globally by surgeons since 2008.

Catch up on what happened in optometry during the week of January 13-January 17.

Previously, ClearVision Optical was Revo’s ECP channel distributor for 8 years.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Focused inSights 2024: Frame Buyers found that 78% of providers display between 200 and 1200 frames on their boards, with 70% of providers updating their inventory quarterly.

The award program includes Transitions Healthy Sight Ambassador, Eyecare Practice of the Year, Retailer of the Year, and Channel Partner of the Year awards.

WAVE Eye Care was developed by EyePrint Prosthetics, Advanced Vision Technologies (AVT), and WAVE Contact Lens System.

The guideline, titled "Care of the Patient with Primary Open-Angle Glaucoma," was developed by the AOA Evidence-based Optometry Guideline Development Group.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

The investigators used National Health and Nutrition Examination Survey data in a cross-sectional study to determine the association between Dietary Inflammatory Index and non-refractive visual impairment from diseases other than cataract and age-related macular degeneration.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

A panelist discusses how prioritizing aggressive treatment of ocular surface disease, particularly Demodex blepharitis, before proceeding with cataract surgery can lead to better surgical outcomes and patient satisfaction.